查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654345

非病毒基因传递技术市场规模、份额、趋势分析报告：按模式、应用、最终用途、地区和细分市场预测，2025-2030 年

Non-viral Gene Delivery Technologies Market Size, Share & Trends Analysis Report By Mode (Chemical, Physical), By Application (Research, Therapeutics), By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

非病毒基因传递市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球非病毒基因传递技术市场规模预计到 2030 年将达到 71.1 亿美元，预测期内（2025-2030 年）的复合年增长率为 12.29%。

该市场的成长是由基因治疗和研究中对安全、可扩展且具有成本效益的病毒载体替代品的需求不断增长所推动的。与病毒方法不同，脂质奈米颗粒 (LNP)、聚合物和电穿孔等非病毒技术具有低免疫抗原性且製造复杂性降低。这些特性使它们非常适合大规模应用，例如基于 mRNA 的疫苗和基于 CRISPR/Cas9 的基因编辑疗法。 Moderna 和 Pfizer-BioNTech 的 mRNA COVID-19 疫苗的成功进一步证明了非病毒递送系统的潜力，并刺激了全球对这一领域的投资。

奈米技术和生物材料的进步进一步加速了这一领域的创新。奈米粒子、脂质体和混合载体正在进行优化，以提高转染效率和标靶递送。随着癌症、罕见遗传疾病和心血管疾病等慢性病的发病率上升，对有效、精准治疗方案的需求呈指数级增长。允许传递大剂量基因和重复给药的非病毒技术对于解决这些未满足的医疗需求至关重要。此外，它们在体外研究和体内治疗应用方面的多功能性使其在生物技术、製药和学术机构中广泛应用。

政府对基因治疗研究的资助和私人投资的增加也是市场成长的主要驱动力。虽然北美和欧洲等地区在研发方面处于领先地位，但中国和印度等亚太新兴国家随着生物技术基础设施和法律规范的发展也迅速进步。此外，生物技术公司和学术机构之间的合作正在推动创新并扩大非病毒递送解决方案的可及性，从而确保它们在快速发展的基因治疗领域的重要性。

非病毒基因传递技术市场报告重点

  • 预计化学品行业将在 2024 年占据最大的收益占有率，并且预计在预测期内将呈现最快的成长率。非病毒基因传递技术的化学模式是由对高效、安全和可扩展的基因传递系统日益增长的需求所驱动。
  • 由于对研究基因功能、表达和调控的多功能、高效且经济高效的工具的需求不断增长，研究市场在 2024 年占据了最大的收益占有率。
  • 根据最终用途，研究和学术机构部门将在 2024 年占据最大的收益占有率，为 48.11%，预计在预测期内将以最快的复合年增长率成长。这种增长是由对研究基因功能、表达和修饰的可靠、高效且经济的方法的需求不断增长所推动的。
  • 到 2024 年，北美地区将占据全球市场的主导地位，市场占有率为 41.25%。该地区拥有先进的医疗基础设施，能够迅速采用创新的基因转移技术。人们对精准医疗的兴趣日益浓厚，以及针对遗传疾病的临床测试的增加进一步推动了市场的成长。此外，政府对基因组研究的措施和资助也促进了非病毒递送技术的使用增加。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 产业分析工具
    • 波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第四章模式业务分析

  • 模式细分仪表板
  • 非病毒基因传递技术市场：模式变异分析
  • 2018 年至 2030 年非病毒基因传递市场规模及趋势分析（按模式）
  • 化学
    • 2018 年至 2030 年化学品市场估计与预测
    • LNP
    • 聚合物
    • 其他的
  • 身体的
    • 2018 年至 2030 年实体市场估计与预测
    • 电穿孔
    • 显微注射
    • 其他的

第五章 应用业务分析

  • 应用程式细分仪表板
  • 非病毒基因传递技术市场：应用趋势分析
  • 2018 年至 2030 年非病毒基因传递市场规模及应用趋势分析
  • 研究
    • 2018 年至 2030 年研究市场估计与预测
  • 治疗
    • 2018 年至 2030 年治疗市场估计与预测
    • 基因治疗
    • 细胞疗法
    • 疫苗

第六章 最终用途业务分析

  • 最终用途细分仪表板
  • 非病毒基因传递技术市场：最终用途变异分析
  • 非病毒基因传递技术市场规模和趋势分析（按最终用途），2018 年至 2030 年
  • 生物技术和生物製药公司
    • 2018 年至 2030 年生物技术和生物製药公司市场估计和预测
  • 研究和学术机构
    • 2018 年至 2030 年研究与学术机构市场估计与预测
  • 其他的
    • 2018 年至 2030 年其他市场估计与预测

第七章。

  • 区域控制面板
  • 2024 年和 2030 年市场规模、预测和趋势分析
  • 北美洲
    • 2018 年至 2030 年北美非病毒基因传递技术市场
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018 至 2030 年欧洲非病毒基因传递技术市场
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018 年至 2030 年亚太地区非病毒基因传递技术市场
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲非病毒基因传递技术市场，2018-2030 年
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 中东和非洲非病毒基因传递技术市场，2018-2030 年
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司分类
  • 战略地图
  • 2024 年企业市场分析
  • 公司简介/上市公司
    • Thermo Fisher Scientific Inc.
    • GenScript
    • Danaher
    • Merck KGaA
    • Bio-Rad Laboratories
    • Altogen Biosystems
    • Lonza
    • Sonidel
    • SIRION BIOTECH GmbH
    • Innovative Cell Technologies, Inc.
Product Code: GVR-4-68040-497-6

Non-viral Gene Delivery Technologies Market Growth & Trends:

The global non-viral gene delivery technologies market size is anticipated to reach USD 7.11 billion by 2030 and grow at a CAGR of 12.29% from 2025 to 2030 during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is driven by the growing demand for safe, scalable, and cost-effective alternatives to viral vectors in gene therapy and research. Unlike viral methods, non-viral technologies such as lipid nanoparticles (LNPs), polymers, and electroporation offer lower immunogenicity and reduced manufacturing complexities. These attributes make them highly suitable for large-scale applications, including mRNA-based vaccines and CRISPR/Cas9-based gene editing therapies. The success of mRNA COVID-19 vaccines by Moderna and Pfizer-BioNTech further validated the potential of non-viral delivery systems, spurring global investment in this sector.

Advancements in nanotechnology and biomaterials are further accelerating innovation in the field. Nanoparticles, lipoplexes, and hybrid carriers are being optimized for enhanced transfection efficiency and targeted delivery. With the rising prevalence of chronic diseases, including cancer, rare genetic disorders, and cardiovascular conditions, the need for effective and precise therapeutic solutions has surged. Non-viral technologies, with their ability to deliver large genetic payloads and support repeat administrations, are pivotal in addressing these unmet medical needs. In addition, their versatility in both in vitro research applications and in vivo therapeutic use cases expands their adoption across biotechnology, pharmaceutical companies, and academic institutes.

The rising government funding and private investments in gene therapy research are also key drivers of market growth. Regions like North America and Europe lead in terms of R&D, but emerging economies in Asia-Pacific, such as China and India, are rapidly advancing due to increasing biotech infrastructure and supportive regulatory frameworks. Furthermore, partnerships between biotech companies and academic institutions are fostering innovation and expanding the accessibility of non-viral delivery solutions, ensuring their relevance in the rapidly evolving field of gene therapy.

Non-viral Gene Delivery Technologies Market Report Highlights:

  • The chemical segment accounted for the largest revenue share in 2024 and is projected to witness the fastest growth rate over the forecast period. The chemical mode of non-viral gene delivery technologies is driven by the increasing demand for efficient, safe, and scalable gene delivery systems.
  • In 2024, research dominated the market with the largest revenue share, driven by the increasing demand for versatile, efficient, and cost-effective tools to investigate gene function, expression, and regulation.
  • By end use, the research and academic institutes segment captured the largest revenue share of 48.11% in 2024 and is expected to experience the fastest CAGR during the forecast period. This growth is fueled by the rising demand for reliable, efficient, and cost-effective approaches to study gene function, expression, and modification.
  • The North American region dominated globally with a market share of 41.25% in 2024. The region benefits from advanced healthcare infrastructure, enabling the rapid adoption of innovative gene delivery techniques. Growing interest in precision medicine and increasing clinical trials focused on genetic disorders further boost market growth. In addition, government initiatives and funding for genomic research contribute to the expanding use of non-viral delivery technologies.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Mode Segment
    • 1.1.2. Application Segment
    • 1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Primary Research
  • 1.6. Information or Data Analysis:
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Validation
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. List of Abbreviations
  • 1.11. Objective

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Adoption in Therapeutics and Research
      • 3.2.1.2. Technological Advancements and Innovation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited Delivery Efficiency for Complex Targets
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Mode Business Analysis

  • 4.1. Mode Segment Dashboard
  • 4.2. Non-viral gene delivery technologies market: Mode Movement Analysis
  • 4.3. Non-viral gene delivery technologies market Size & Trend Analysis, by Mode, 2018 to 2030 (USD Million)
  • 4.4. Chemical
    • 4.4.1. Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. LNPs
      • 4.4.2.1. LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Polymers
      • 4.4.3.1. Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Others
      • 4.4.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Physical
    • 4.5.1. Physical market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.2. Electroporation
      • 4.5.2.1. Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.3. Microinjection
      • 4.5.3.1. Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Application Business Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. Non-viral gene delivery technologies market Application Movement Analysis
  • 5.3. Non-viral gene delivery technologies market Size & Trend Analysis, by mode, 2018 to 2030 (USD Million)
  • 5.4. Research
    • 5.4.1. Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Therapeutics
    • 5.5.1. Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. Gene Therapy
      • 5.5.2.1. Gene Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Cell Therapy
      • 5.5.3.1. Cell Therapy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. Vaccines
      • 5.5.4.1. Vaccines market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. End Use Business Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. Non-viral gene delivery technologies market End Use Movement Analysis
  • 6.3. Non-viral gene delivery technologies market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Biotechnology and Biopharmaceutical Companies
    • 6.4.1. Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Research and academic institutes
    • 6.5.1. Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis by mode, application, end use

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecast and Trend Analysis, 2024 & 2030
  • 7.3. North America
    • 7.3.1. North America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. U.S. non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Canada non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Mexico non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. UK non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Germany non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. France non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Italy non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Spain non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Denmark non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key Country Dynamics
      • 7.4.8.2. Competitive Scenario
      • 7.4.8.3. Regulatory Framework
      • 7.4.8.4. Sweden non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key Country Dynamics
      • 7.4.9.2. Competitive Scenario
      • 7.4.9.3. Regulatory Framework
      • 7.4.9.4. Norway non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Japan non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. China non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Competitive Scenario
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. India non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Competitive Scenario
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Australia non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Competitive Scenario
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Thailand non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.5.7. South Korea
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Competitive Scenario
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. South Korea Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Brazil non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Argentina non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Competitive Scenario
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. South Africa non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Competitive Scenario
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Saudi Arabia Non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Competitive Scenario
      • 7.7.4.3. Regulatory Framework
      • 7.7.4.4. UAE non-viral gene delivery technologies market, 2018 - 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key Country Dynamics
      • 7.7.5.2. Competitive Scenario
      • 7.7.5.3. Regulatory Framework
      • 7.7.5.4. Kuwait non-viral gene delivery technologies market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2024
  • 8.4. Company Profiles/Listing
    • 8.4.1. Thermo Fisher Scientific Inc.
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Strategic Initiatives
    • 8.4.2. GenScript
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Strategic Initiatives
    • 8.4.3. Danaher
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Strategic Initiatives
    • 8.4.4. Merck KGaA
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Strategic Initiatives
    • 8.4.5. Bio-Rad Laboratories
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Strategic Initiatives
    • 8.4.6. Altogen Biosystems
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Strategic Initiatives
    • 8.4.7. Lonza
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Strategic Initiatives
    • 8.4.8. Sonidel
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Strategic Initiatives
    • 8.4.9. SIRION BIOTECH GmbH
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Strategic Initiatives
    • 8.4.10. Innovative Cell Technologies, Inc.
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global non-viral gene delivery technologies market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 4 Global non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 8 North America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 9 North America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 11 U.S. Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 12 U.S. Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 14 Canada Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Canada Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 16 Mexico Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 17 Mexico Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 18 Mexico Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 19 Europe Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 21 Europe Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 22 Europe Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 23 Germany Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 24 Germany Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 25 Germany Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 27 UK Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 29 France Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 30 France Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 31 France Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 32 Italy Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 33 Italy Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Italy Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 35 Spain Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 36 Spain Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Spain Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 38 Denmark Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 39 Denmark Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Denmark Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 41 Sweden Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 42 Sweden Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Sweden Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 44 Norway Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 45 Norway Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 46 Norway Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 51 China Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 52 China Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 53 China Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 54 Japan Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 55 Japan Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Japan Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 57 India Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 58 India Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 59 India Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 60 South Korea Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 61 South Korea Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 62 South Korea Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 63 Australia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 64 Australia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Australia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 66 Thailand Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 67 Thailand Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 68 Thailand Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 69 Latin America Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 71 Latin America Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 72 Latin America Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 73 Brazil Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 74 Brazil Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 75 Brazil Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 76 Argentina Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 77 Argentina Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 78 Argentina Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 79 Middel East & Africa Non-viral gene delivery technologies market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 83 South Africa Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 84 South Africa Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 85 South Africa Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 89 UAE Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 90 UAE Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 91 UAE Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Non-viral gene delivery technologies market, by mode, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Non-viral gene delivery technologies market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Non-viral gene delivery technologies market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Non-viral gene delivery technologies market: market outlook
  • Fig. 7 Laser capture microdissection competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Non-viral gene delivery technologies market driver impact
  • Fig. 10 Non-viral gene delivery technologies market restraint impact
  • Fig. 11 Non-viral gene delivery technologies market: Mode movement analysis
  • Fig. 12 Non-viral gene delivery technologies market: Mode outlook and key takeaways
  • Fig. 13 Chemical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Physical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 LNPs market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Polymers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Electroporation market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Microinjection market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Non-viral gene delivery technologies market: Application movement analysis
  • Fig. 22 Non-viral gene delivery technologies market: Application outlook and key takeaways
  • Fig. 23 Research market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Gene Therapy market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 26 Cell Therapy market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 27 Vaccines market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Non-viral gene delivery technologies market: End use movement analysis
  • Fig. 29 Non-viral gene delivery technologies market: End use outlook and key takeaways
  • Fig. 30 Biotechnology and biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Research and academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 North America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 U.S. non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Canada non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Europe non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 UK non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Germany non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 France non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Norway non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Asia Pacific Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 China non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Japan non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 India non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Thailand non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Argentina Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Middle East and Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 South Africa Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Saudi Arabia Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 UAE Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Kuwait Non-viral gene delivery technologies market estimates and forecasts, 2018 - 2030 (USD Million)